Sarika N Rao1, Mark Zafereo2, Ramona Dadu1, Naifa L Busaidy1, Kenneth Hess3, Gilbert J Cote1, Michelle D Williams4, William N William5, Vlad Sandulache2, Neil Gross2, G Brandon Gunn6, Charles Lu5, Renata Ferrarotto5, Stephen Y Lai2, Maria E Cabanillas1. 1. 1 Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, Texas. 2. 2 Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center , Houston, Texas. 3. 3 Department of Biostatistics, The University of Texas MD Anderson Cancer Center , Houston, Texas. 4. 4 Department of Pathology, The University of Texas MD Anderson Cancer Center , Houston, Texas. 5. 5 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas. 6. 6 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas.
Abstract
BACKGROUND: Anaplastic thyroid cancer (ATC) is one of the most lethal forms of cancer with a high mortality rate. Current guidelines support surgery for resectable ATC followed by external beam radiation therapy (EBRT) with or without chemotherapy. Treatment for those who are unresectable is palliative. Our goal was to examine first-line therapies as well as the role of genomic profiling in an effort better understand how to approach ATC. METHODS: This is a retrospective study of ATC patients who were seen at our institution from January 2013 to October 2015. Median overall survival (OS) and time to treatment failure (TTF) were calculated by the Kaplan-Meier method. RESULTS: Fifty-four patients were included. Median age at diagnosis was 63 years and 29/54 (54%) were women. The majority had stage IVC disease at diagnosis (50%), followed by IVB (32%), and IVA (18%). Approximately 93% had somatic gene testing. Initial treatment was surgery in 23 patients, EBRT with or without radiosensitizing chemotherapy in 29 patients, and systemic chemotherapy in 2 patients. Nineteen patients had all three treatment modalities. For the entire cohort, median OS was 11.9 months with 39% survival at 1 year and median TTF was 3.8 months. The majority of patients (74%) developed new distant metastasis or progression of existing metastatic disease. Patients who received trimodal therapy consisting of surgery, EBRT, and chemotherapy had a median OS of 22.1 months versus 6.5 months in those who received dual therapy with EBRT and chemotherapy (p = 0.0008). The TTF was the same in the two groups (7.0 and 6.5 months, respectively). Men were three times more likely to die from ATC than women (p = 0.0024). No differences in OS or TTF were noted based on tumor size (5 cm cutoff), age (60 years cutoff), or presence of any mutation. There was a trend toward shorter TTF in patients with somatic mutations in TP53. CONCLUSION: Patients with ATC amenable to aggressive tri-modal therapy demonstrate improved survival. The short TTF, due primarily to distant metastatic disease, highlights the potential opportunity for improved outcomes with earlier initiation of systemic therapy including adjuvant or neoadjuvant therapy.
BACKGROUND:Anaplastic thyroid cancer (ATC) is one of the most lethal forms of cancer with a high mortality rate. Current guidelines support surgery for resectable ATC followed by external beam radiation therapy (EBRT) with or without chemotherapy. Treatment for those who are unresectable is palliative. Our goal was to examine first-line therapies as well as the role of genomic profiling in an effort better understand how to approach ATC. METHODS: This is a retrospective study of ATC patients who were seen at our institution from January 2013 to October 2015. Median overall survival (OS) and time to treatment failure (TTF) were calculated by the Kaplan-Meier method. RESULTS: Fifty-four patients were included. Median age at diagnosis was 63 years and 29/54 (54%) were women. The majority had stage IVC disease at diagnosis (50%), followed by IVB (32%), and IVA (18%). Approximately 93% had somatic gene testing. Initial treatment was surgery in 23 patients, EBRT with or without radiosensitizing chemotherapy in 29 patients, and systemic chemotherapy in 2 patients. Nineteen patients had all three treatment modalities. For the entire cohort, median OS was 11.9 months with 39% survival at 1 year and median TTF was 3.8 months. The majority of patients (74%) developed new distant metastasis or progression of existing metastatic disease. Patients who received trimodal therapy consisting of surgery, EBRT, and chemotherapy had a median OS of 22.1 months versus 6.5 months in those who received dual therapy with EBRT and chemotherapy (p = 0.0008). The TTF was the same in the two groups (7.0 and 6.5 months, respectively). Men were three times more likely to die from ATC than women (p = 0.0024). No differences in OS or TTF were noted based on tumor size (5 cm cutoff), age (60 years cutoff), or presence of any mutation. There was a trend toward shorter TTF in patients with somatic mutations in TP53. CONCLUSION:Patients with ATC amenable to aggressive tri-modal therapy demonstrate improved survival. The short TTF, due primarily to distant metastatic disease, highlights the potential opportunity for improved outcomes with earlier initiation of systemic therapy including adjuvant or neoadjuvant therapy.
Authors: Annemarie T Swaak-Kragten; Johannes H W de Wilt; Paul I M Schmitz; Marijke Bontenbal; Peter C Levendag Journal: Radiother Oncol Date: 2009-03-26 Impact factor: 6.280
Authors: Tae Yong Kim; Kyung Won Kim; Tae Sik Jung; Jung Min Kim; Sun Wook Kim; Ki-Wook Chung; Eun Young Kim; Gyungyub Gong; Young Lyun Oh; Soo Youn Cho; Ka Hee Yi; Won Bae Kim; Do Joon Park; Jae Hoon Chung; Bo Youn Cho; Young Kee Shong Journal: Head Neck Date: 2007-08 Impact factor: 3.147
Authors: Briseis A Kilfoy; Susan S Devesa; Mary H Ward; Yawei Zhang; Philip S Rosenberg; Theodore R Holford; William F Anderson Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-03-17 Impact factor: 4.254
Authors: Alyaksandr V Nikitski; Susan L Rominski; Vincenzo Condello; Cihan Kaya; Mamta Wankhede; Federica Panebianco; Hong Yang; Daniel L Altschuler; Yuri E Nikiforov Journal: Thyroid Date: 2019-08-16 Impact factor: 6.568
Authors: Sibo Tian; Jeffrey M Switchenko; Teng Fei; Robert H Press; Mustafa Abugideiri; Nabil F Saba; Taofeek K Owonikoko; Amy Y Chen; Jonathan J Beitler; Walter J Curran; Theresa W Gillespie; Kristin A Higgins Journal: Head Neck Date: 2019-12-16 Impact factor: 3.147
Authors: Saad A Khan; Bo Ci; Yang Xie; David E Gerber; Muhammad S Beg; Steven I Sherman; Maria E Cabanillas; Naifa L Busaidy; Barbara A Burtness; Andreas M Heilmann; Mark Bailey; Jeffrey S Ross; David J Sher; Siraj M Ali Journal: Head Neck Date: 2019-02-13 Impact factor: 3.147
Authors: Dan Fan; Jennifer Ma; Andrew C Bell; Andries H Groen; Kyrie S Olsen; Benjamin H Lok; Jonathan E Leeman; Erik Anderson; Nadeem Riaz; Sean McBride; Ian Ganly; Ashok R Shaha; Eric J Sherman; C Jillian Tsai; Jung J Kang; Nancy Y Lee Journal: Cancer Date: 2019-10-08 Impact factor: 6.860
Authors: Anastasios Maniakas; Ramona Dadu; Naifa L Busaidy; Jennifer R Wang; Renata Ferrarotto; Charles Lu; Michelle D Williams; G Brandon Gunn; Marie-Claude Hofmann; Gilbert Cote; Jared Sperling; Neil D Gross; Erich M Sturgis; Ryan P Goepfert; Stephen Y Lai; Maria E Cabanillas; Mark Zafereo Journal: JAMA Oncol Date: 2020-09-01 Impact factor: 31.777
Authors: Vivek Subbiah; Robert J Kreitman; Zev A Wainberg; Jae Yong Cho; Jan H M Schellens; Jean Charles Soria; Patrick Y Wen; Christoph Zielinski; Maria E Cabanillas; Gladys Urbanowitz; Bijoyesh Mookerjee; Dazhe Wang; Fatima Rangwala; Bhumsuk Keam Journal: J Clin Oncol Date: 2017-10-26 Impact factor: 44.544
Authors: Keith C Bible; Electron Kebebew; James Brierley; Juan P Brito; Maria E Cabanillas; Thomas J Clark; Antonio Di Cristofano; Robert Foote; Thomas Giordano; Jan Kasperbauer; Kate Newbold; Yuri E Nikiforov; Gregory Randolph; M Sara Rosenthal; Anna M Sawka; Manisha Shah; Ashok Shaha; Robert Smallridge; Carol K Wong-Clark Journal: Thyroid Date: 2021-03 Impact factor: 6.568